Menstrual and Dysmenorrhea Outcomes After Thermachoice III: A 2-Year Prospective Study

Abstract Objective: The aim of this study was the evaluation of menstrual and dysmenorrhea outcomes 24 months after in office Thermachoice III endometrial ablations. Design: This was a prospective, single-arm cohort study. Materials and Methods: Patient recruitment was from November 2006 to November 2007, at the Women's Specialty Center, Dallas, TX. The Center is a community-based obstetrical and gynecologic medical clinic serving a largely lower socioeconomic patient population. Interventions included office-based diagnostic hysteroscopy, dilation and curettage, and Thermachoice III endometrial ablation under local analgesia. The primary outcome measure was menorrhagia resolution with categories of amenorrhea, hypomenorrhea, or failure. Failure was defined as subsequent menstrual flow similar to pretreatment state, need for further surgical/medical therapy, or any abnormal bleeding that was troublesome to the patient. Hemoglobin comparisons were included as an objective measure of therapy success. The se...

[1]  H. Chapa,et al.  In-office endometrial ablation using a third-generation uterine balloon therapy system: 12-month prospective follow-up on menstrual patterns and dysmenorrhea impact. , 2009, The Journal of reproductive medicine.

[2]  H. Chapa,et al.  In-office endometrial ablation and clinical correlation of reduced menstrual blood loss and effects on dysmenorrhea and premenstrual symptomatology. , 2009, The Journal of reproductive medicine.

[3]  A. Weaver,et al.  Prediction of Treatment Outcomes After Global Endometrial Ablation , 2009, Obstetrics and gynecology.

[4]  L. Learman,et al.  Probability of Hysterectomy After Endometrial Ablation , 2008, Obstetrics and gynecology.

[5]  H. Chapa.  Utility of in-office endometrial ablation: a prospective cohort study of endometrial ablation under local anesthesia. , 2008, The Journal of reproductive medicine.

[6]  Jeff Evans.  Hydroxychloroquine ‘Probably Safe’ in Pregnancy , 2005 .

[7]  G. Vilos.  Hysteroscopic and nonhysteroscopic endometrial ablation. , 2004, Obstetrics and gynecology clinics of North America.

[8]  F. Loffer.  Improving results of hysteroscopic submucosal myomectomy for menorrhagia by concomitant endometrial ablation. , 2004, Journal of minimally invasive gynecology.

[9]  Jay Cooper,et al.  Summary of safety and effectiveness data from FDA: a valuable source of information on the performance of global endometrial ablation devices. , 2004, The Journal of reproductive medicine.

[10]  S. Gurtcheff,et al.  Complications Associated With Global Endometrial Ablation: The Utility of the MAUDE Database , 2003, Obstetrics and gynecology.

[11]  P. Reid,et al.  Assessment of menstrual blood loss using a pictorial chart: a validation study , 2000, BJOG : an international journal of obstetrics and gynaecology.

[12]  F. Tresserra,et al.  Morphological changes in hysterectomies after endometrial ablation. , 1999, Human reproduction.

[13]  W R Meyer,et al.  Thermal Balloon and Rollerball Ablation to Treat Menorrhagia: A Multicenter Comparison , 1998, Obstetrics and gynecology.

[14]  Badger,et al.  Prediction of endometrial ablation success by preoperative findings. , 1998, Primary care update for Ob/Gyns.

[15]  D. Parkin.  Prognostic factors for success of endometrial ablation and resection , 1998, The Lancet.